FDA Registered
+1 (657) 676-9828
Dovita Nutrition Health
Back to News & Insights
Regulatory

FDA Issues New Guidance on Probiotic Supplement Labeling Requirements

June 28, 2026
FDA Issues New Guidance on Probiotic Supplement Labeling Requirements

The FDA released updated labeling requirements for probiotic supplements, representing the most significant regulatory change for probiotic manufacturers in over a decade.

New Labeling Requirements

1. **Strain-Level Identification**: Labels must now specify the exact strain designation (e.g., Lactobacillus rhamnosus GG, not just "Lactobacillus rhamnosus")

Our Compliance Status

All Dovita-manufactured probiotic products already comply with the new standards:

Manufacturing Capabilities

- Stability testing to verify CFU counts through shelf life

We provide regulatory guidance to all OEM partners to ensure their probiotic product labels meet the new FDA requirements.

Frequently Asked Questions

Related Products

Lactobacillus Rhamnosus GG 10B CFUBifidobacterium Longum CapsulesMulti-Strain Probiotic Complex
Request a Quote for This Product
Previous Article

Collagen Peptides Powder: The Fastest-Growing Supplement Category in 2026

Next Article

Ashwagandha KSM-66 Tablets: Meeting the Rising Demand for Stress Relief Supplements

More from Regulatory

21 CFR Part 111 Compliance: What Every Supplement Brand Owner Needs to Know About cGMP Manufacturing
Regulatory
July 24, 2026

21 CFR Part 111 Compliance: What Every Supplement Brand Owner Needs to Know About cGMP Manufacturing

21 CFR Part 111 is the FDA's Current Good Manufacturing Practice (cGMP) regulation for dietary supplements, establishing minimum requirements for manufacturing, packaging, labeling, and holding operations. Key compliance areas include: component testing and identity verification, master manufacturing records (MMR) and batch production records (BPR), quality control procedures for each production step, and finished product testing for identity, purity, strength, and composition. Non-compliance can result in FDA warning letters, product recalls, and import holds. Dovita Nutrition Health LLC maintains full 21 CFR Part 111 compliance at our U.S. facility, with annual third-party cGMP audits achieving zero deficiency ratings. We provide complete documentation packages to our OEM partners including CoA, batch records, and facility audit reports.

FDA Updates DSHEA Enforcement Priorities for 2026: What Supplement Manufacturers Need to Know
Regulatory
July 20, 2026

FDA Updates DSHEA Enforcement Priorities for 2026: What Supplement Manufacturers Need to Know

The FDA has announced updated enforcement priorities under the Dietary Supplement Health and Education Act (DSHEA) for 2026, focusing on adulterated products, unapproved new dietary ingredients (NDIs), and misleading structure/function claims. As an FDA-registered and cGMP-certified facility, Dovita Nutrition Health LLC maintains full compliance with all current and proposed regulations. We provide regulatory guidance to all OEM partners to ensure label claims, ingredient sourcing, and manufacturing processes meet FDA standards.